期刊文献+

肝硬化腹水患者血浆AVP和尿AQP2的检测及临床意义 被引量:2

下载PDF
导出
摘要 目的探讨检测肝硬化腹水患者血浆AVP和尿液AQP2含量的临床意义。方法选择2009年1月-2011年9月该院收治的肝硬化患者100例,分为腹水组60例,无腹水组40例,观察2组患者的血浆AVP水平和24h尿液AQP2水平测定值。结果肝硬化腹水组患者血浆AVP水平和尿液AQP2含量明显高于无腹水组,差异有统计学意义(P<0.05)。结论肝硬化腹水患者存在血浆AVP和肾脏AQP2含量的增加,而且血浆AVP的含量影响肾脏AQP2的表达。
作者 王建华
出处 《临床合理用药杂志》 2013年第17期155-155,共1页 Chinese Journal of Clinical Rational Drug Use
基金 邯郸市科技支撑项目(No:1223108086-9)
  • 相关文献

参考文献5

二级参考文献32

  • 1张鸽.血管加压素V_(1a)/V_2受体拮抗剂Conivaptan[J].药学进展,2005,29(3):144-144. 被引量:3
  • 2李震花,葛志明.非选择性精氨酸加压素受体拮抗药与心力衰竭[J].新医学,2006,37(4):274-274. 被引量:2
  • 3Decaux G, Soupart A, Vassart G. Non - peptide arginine - vasopressin antagonists:the vaptans. Lancet,2008,371 (9624) : 1624.
  • 4Hoom E J, Zietse R. Vasopressin - receptor antagonists. Future Cardiol,2010,6(4) :523.
  • 5Steinwall M,Bossmar T,Gaud C,et al. Inhibitory effects of SR49059 on oxytocin and vasopressin induced uterine contractions in non - pregnant women. Acta Obstet Gynecol Scand,2004,83 :12.
  • 6Steinwall M,Bossmar T,Brouard R,e? al. The effect of relcovaptan( SR 49059) ,an orally active vasopressin Via receptor antagonist,on uterine contraction in preterm labor. Gynecol Endocrinol, 2005 ,20 ( 2 ) : 104.
  • 7Tahara A,Tsukada J,Tomura Y,et al. Effects of YM218 , a nonpeptide vasopressin VIA receptor - selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res,2005 ,51 (3 ) :275.
  • 8Ami^shieva A V,Ilnitskaya S I,Nikolin V P,et al. Effect of vasopres- sin Vlb receptor antagonist, SSR149415 , on anxiety - like behavior and Lewis lung carcinoma metastasis in mice. Exp Oncol,2011,33(3) :126.
  • 9Serradeil - Le G C, Wagnon J, Simiand ] ,et al. Characterization of (2S, 4R) - 1 - [5 - chloro -1 - [ (2,4 - dimethoxyphenyl) ] sulfonyl] - 3 -(2- methoxy - phenyl)-2-oxo -2,3 - dihydro - 1H - indol -3 -yl] - 4 - hydroxy - N,N - dimethyl - 2 - pyrrolidine carboxamide (SSR149415),a selective and orally - active vasopressin Vlb receptor antagonist. J Pharmacol Exp Ther,2002,300(3) :1122.
  • 10Griebel G,Simiand J,Serradeil - he G C,et al. Anxiolytic - and antidepressant -like effects of the non - peptide vasopressin Vlb - receptor antagonist, SSR149415 , suggest an innovative approach for the treatment of stress - related disorders. Proc Natl Acad Sci USA,2002,99 (9): 6370.

共引文献14017

同被引文献32

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部